Drugs in MeSH Category Analgesics

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms Co	PREGABALIN	pregabalin	CAPSULE;ORAL	209743-006	Jul 19, 2019	AB	RX	No	No
Lupin Ltd	DULOXETINE HYDROCHLORIDE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	090694-002	Dec 11, 2013	AB	RX	No	No
Macleods Pharms Ltd	DULOXETINE HYDROCHLORIDE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	204815-001	Mar 23, 2017	AB	RX	No	No
Msn	PREGABALIN	pregabalin	CAPSULE;ORAL	209357-004	Jul 19, 2019	AB	RX	No	No
Mylan Labs Ltd	MAGNESIUM SULFATE IN PLASTIC CONTAINER	magnesium sulfate	INJECTABLE;INJECTION	209911-002	Sep 14, 2018	AP	RX	No	No
Upjohn	LYRICA CR	pregabalin	TABLET, EXTENDED RELEASE;ORAL	209501-003	Oct 11, 2017	AB	RX	Yes	Yes	10,022,447*PED				Y

Analgesics Market Analysis and Financial Projection

The global analgesics market is undergoing significant transformation, driven by technological innovation, shifting regulatory landscapes, and evolving patient needs. Below, we analyze the market dynamics and patent trends for drugs classified under the National Library of Medicine's Medical Subject Headings (MeSH) class "Analgesics."

---

Market Dynamics

Current Valuation and Growth Projections

• The analgesics market was valued between $22.14 billion (narrower scope)[1] and $56.32 billion (broader scope)[4] in 2024, with projections reaching $79.86–$81.06 billion by 2033–2034[4][10]. This discrepancy reflects varying definitions of market scope, including/excluding opioid analgesics.
• Growth is fueled by a 3.2–6.7% CAGR, attributed to:
  • Rising prevalence of chronic pain (arthritis, neuropathic pain, migraines)[4][10].
  • Aging populations globally (19% of adults suffer chronic pain)[11].
  • Shift toward non-opioid alternatives amid opioid addiction concerns[7][11].

Regional Dominance and Key Players

• North America leads with >32.8% market share[4], driven by high healthcare spending and advanced R&D. The U.S. alone accounts for $12.87 billion (2024)[10].
• Major manufacturers include Bayer, Pfizer, Johnson & Johnson, and Novartis[1][4].

Segment Trends

• Non-opioid analgesics: Demand surged due to opioid crisis fallout. For example, LSU Health’s non-addictive painkiller received FDA Fast Track status in 2024[4].
• Opioid analgesics: A niche persists for severe pain (e.g., cancer), with the opioid market reaching $48.47 billion by 2025 despite regulatory scrutiny[7][14].

---

Patent Landscape

Emerging Technologies

1. Digital Pills with Ingestible Sensors
   Patents focus on mobile clinical monitoring and targeted drug delivery. Key areas include:

   • Mental health, HIV/AIDS, and pain control[2][9].
   • Leaders: U.S., EPO, and China[2].

2. NaV1.8 Inhibitors
   Next-gen non-opioid analgesics like VX-548 (Vertex Pharmaceuticals) target sodium channels for neuropathic pain. Fast-follower patents from Hengrui and Shanghai Huilun modify molecular structures to enhance efficacy[8].

3. Long-Acting Therapies

   • Adolore BioTherapeutics’ CA8 gene therapy (patented in Japan) enables localized, long-lasting pain relief without systemic opioid effects[12].
   • Cyclodextrin-based formulations improve drug stability and reduce side effects[13].

Strategic Patenting Trends

• Geographic Focus: 70% of patents originate from the U.S. and EPO[16].
• Therapeutic Areas: Mental health, oncology, and diabetes dominate[2][8].
• Collaborative R&D: Partnerships between pharma giants and biotech firms accelerate innovation (e.g., Vertex’s licensing deals)[8].

---

Key Market-Patent Synergies

Market Trend	Patent Innovation	Example
Demand for non-opioid drugs	NaV1.8 inhibitors, digital pills	VX-548[8]
Long-term pain management	Extended-release formulations, gene therapies	CA8 therapy[12]
Safety concerns	Abuse-deterrent opioids, cyclodextrin complexes	Oxycodone-cyclodextrin complexes[13]

---

Challenges and Opportunities

• Regulatory Hurdles: Stricter opioid prescriptions limit growth but spur non-opioid R&D[11].
• Competition: 47 patents for VX-548 derivatives highlight intense innovation in NaV1.8 space[8].
• Future Outlook: Digital health integration (e.g., sensor-enabled pills) and biologics are poised to redefine pain management[2][12].

---

This interplay of market forces and patent activity underscores a industry-wide pivot toward safer, precision-driven analgesics. While opioids retain a role in severe pain, innovation is increasingly channeled into overcoming addiction risks and enhancing therapeutic efficacy.

References

1. https://central.newschannelnebraska.com/story/52491948/analgesics-market-industry-insights-strategic-trends-and-forecast-for-2025
2. https://pubmed.ncbi.nlm.nih.gov/36015173/
3. https://meshb.nlm.nih.gov/record/ui?ui=D000700
4. https://www.imarcgroup.com/analgesics-market
5. https://patents.google.com/patent/US3141823A/en
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9368481/
7. https://www.futuremarketinsights.com/reports/opioid-analgesics-market
8. https://synapse.patsnap.com/blog/breakthrough-pain-relief-innovation-patent-exploration-of-next-generation-nav18-inhibitors
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC9415622/
10. https://www.precedenceresearch.com/analgesics-market
11. https://www.coherentmarketinsights.com/industry-reports/global-analgesics-market
12. https://adolore.com/adolore-biotherapeutics-announces-issuance-of-first-japanese-patent-covering-ca8-long-acting-local-analgesic-therapies-to-treat-chronic-pain/
13. https://pubmed.ncbi.nlm.nih.gov/25960079/
14. https://www.persistencemarketresearch.com/market-research/opioids-market.asp
15. https://journals.indexcopernicus.com/api/file/viewByFileId/1969266
16. https://ceur-ws.org/Vol-2032/om2017_Tpaper4.pdf
17. https://health.ec.europa.eu/document/download/aa0c2eeb-ce0e-4fc7-bf67-2c3cc3b8ebd4_en